Anónimo. FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Risks may include suicidal thoughts or actions. U.S. Food and Drug Administration 2020:4 de marzo. [Ref.ID 103559]

Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018;319:12 de junio. [Ref.ID 102780]

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

Law SWY, Wong AYS, Anand S, Wong ICK, Chan EW. Neurospychiatric events associated with leukotriene-modifying agents: a systematic review. Drug Saf 2018;41:marzo. [Ref.ID 102559]

Henriksen DP, Davidsen JR, Laursen CB, Christiansen A, Damkier P, Hallas J, Pottegård A. Montelukast use — A 19-year nationwide drug utilisation study. Eur J Clin Pharmacol 2017;73:1297-304. [Ref.ID 102083]

Aldea Perona A, García-Sáiz M, Sanz Álvarez E. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase. Drug Saf 2016;39:69-78. [Ref.ID 100084]

Rudmik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA 2015;314:926-39. [Ref.ID 99516]

Loymans RJB, Gemperli A, Cohen J, Rubinstein SM, Sterk PJ, Reddel HK, Jüni P, Ter Riet G. Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ 2014;348:g3009. [Ref.ID 98004]

Anónimo. Comportements violents envers autrui sous l'effet de médicaments. Prescrire 2014;34:110-3. [Ref.ID 97126]

Anónimo. Montelukast - Neuropsychiatric risks. Australian Prescriber 2013;4:1. [Ref.ID 95148]

Anónimo. Genes after LABA response. Prescribing Advice for GPs 2013:8 de enero. [Ref.ID 94621]

Anónimo. Long-acting beta2 agonists for childhood asthma. Australian Prescriber 2012;35:111-3. [Ref.ID 93160]

Parle J, Ross N, Jones J. Investigating beneficial drug reactions. BMJ 2012;344:35. [Ref.ID 92186]

Ducharme F. Leukotriene receptor antagonists as first line or add-on treatment for asthma. BMJ 2011;343:705-6. [Ref.ID 91735]

Ducharme FM. Leukotriene receptor antagonists as first line or add-on treatment for asthma. BMJ 2011;343:d5314. [Ref.ID 91466]

Schumock GT, Lee TA, Joo MJ, Valuck RJ, Stayner LT, Gibbons RD. Association between leukotriene-modifying agents and suicide: what is the evidence?. Drug Saf 2011;34:533-44. [Ref.ID 90892]

Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76. [Ref.ID 89970]

Cumming J, Mays N, Daubé J. How New Zealand has contained expenditure on drugs. BMJ 2010;340:1224-6. [Ref.ID 88636]

Lemanske Jr RF, Mauger T, Sorkness CA, Jackson DJ, Boehmer SJ, Martínez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW, Larsen G, Morgan WJ, Moss MH, Spahn JD, Taussig LM, for the Childhood Asthma Research and Education (CARE) Network of the National Heart Lung and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010;362:975-85. [Ref.ID 88070]

Wallestedt SM, Brunlöf G, Sundström A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009;18:858-64. [Ref.ID 86565]